Abeona Therapeutics Inc Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : The first one I have is on EB-101. Wondering if you think this data top line readout next year could include any longer-term findings beyond the 6-month end point since some of these patients were enrolled early on ahead of the pandemic. And then could you speak to the importance of your durability data from both this trial, and then, of course, the Phase I/II trial when potentially filing for BLA given the FDA's stance and focus on the effects across cell and gene therapies and durability? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 17, 2021 / 1:30PM, ABEO.OQ - Q3 2021 Abeona Therapeutics Inc Earnings Call

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Okay, appreciate that. And then I had a question regarding the potential and exploration of strategic partnerships. So understand that your late-stage pipeline is rare disease focus and that the ophthalmology pipeline, while not disclosed, you have indicated that some of these indications are a little bit larger. So wondering if we should be thinking -- or if the company is evaluating things on a geography basis. So perhaps are there certain regions where these diseases are more impacted? And then also separately, looking at the earlier pipeline, the AIM capsid library. Could you discuss some areas that could be attractive for somebody to evaluate, including perhaps how some of these capsids could address some of the limitations that are currently observed in AAV-based gene therapies?